GB-0895
Generate:Biomedicines: company profile
Phase 3 registry
Since , the date of the source that reports this phase.
Summary
GB-0895 is a program from Generate:Biomedicines. The source describes it as antibody. It is being developed for severe asthma. ClinicalTrials.gov lists it at Phase 3 (recruiting) under NCT07359846, NCT07276724. The AI role named in the source is protein design. Registry records: NCT07359846, Phase 3, recruiting, updated Oct 20, 2026; NCT07276724, Phase 3, recruiting, updated Oct 22, 2026. About the company, based in United States: Flagship-founded generative biology platform that designs protein therapeutics computationally; lead asset GB-0895 (anti-TSLP, golukibart) is in Phase 3 for severe asthma. The latest dated source is from Oct 4, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Generate:Biomedicines
- Indication
- Severe asthma
- Therapeutic area
- Respiratory
- Modality
- Antibody
- AI role
- Protein design
- Phase in the source
- Phase 3, as of Oct 4, 2026
- Phase source
- Registry
- Board column
- Phase 3
AI evidence
AI source: Company
“GB-0895 was designed with Generate’s generative biology platform, which integrates proprietary machine-learning models with high-throughput experimentation.”
Trial records
- NCT07359846 on ClinicalTrials.gov (opens in new tab) Phase 3 Recruiting Updated
- NCT07276724 on ClinicalTrials.gov (opens in new tab) Phase 3 Recruiting Updated
Milestone timeline
-
ClinicalTrials.gov record: Phase 3
-
NCT07359846 record updated
Phase 3, Recruiting
-
NCT07276724 record updated
Phase 3, Recruiting
About Generate:Biomedicines
Flagship-founded generative biology platform that designs protein therapeutics computationally; lead asset GB-0895 (anti-TSLP, golukibart) is in Phase 3 for severe asthma.
Spot an error? Tell me and I'll fix it.